Myelodysplastische Syndrome: Diagnostik und Therapie

Zusammenfassung

Die vorliegende Arbeit soll einen Überblick über Diagnostik und Therapie der myelodysplastischen Syndrome (MDS) darstellen, aber auch aktuelle wissenschaftliche Fragestellungen zur Ätiopathogenese, Pathophysiologie und Klassifikation der myeloischen Neoplasien erläutern, die den Blickwinkel auf die MDS in mancher Hinsicht erweitern können und möglicherweise in Zukunft auch in der Klinik Berücksichtigung finden werden.

Abstract

This article is dedicated to provide an overview about diagnosis and therapies for myelodysplastic syndromes (MDS). Additionally, an insight on current research regarding pathogenesis, pathophysiology and classification of myeloid neoplasia is given which may consecutively be transferred into clinical practice in the future.

Schlüsselwörter

MDS - hämatopoetische Stammzellen - Prognose - Diagnose

Key words

MDS - hematopoietic stem cells - prognosis - diagnosis

Publication History

Article published online:
01 December 2020

• Literatur

• 1 Kuendgen A, Nomdedeu M, Tuechler H. et al Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia 2020; DOI: 10.1038/s41375-020-0917-7. . Online ahead of print
• 2 Jaiswal S, Natarajan P, Ebert BL. Clonal Hematopoiesis and Atherosclerosis. NEJM 2017; 377 (14) 1401-1402 . doi:10.1056/NEJMc1710381
• 3 Goodley L, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood 2017; 130: 424-432 . doi10.1182/blood-2017-02-735290
• 4 Hofmann WK, Platzbecker U, Stauder R. et al Leitlinie Myelodysplastische Syndrome, Onkopedia, Deutsche Gesellschaft für Hämatologie und Onkologie. 2020 http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/md
• 5 Hasserjian R, Orazi A, Brunning RD. et al Myelodysplastic syndromes, overview. In: Swerdlow et al (Edt): WHO proposals for the classification of tumours of myeloid and lymphoid tissues. Lyon: IARC press; 2016
• 6 Schanz J, Tüchler H, Sole F. et al New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30 (08) 820-829 . doi:10.1200/JCO.2011.35.6394
• 7 Papaemmanuil E, Gerstung M, Malcovati L. et al Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3527 . doi:10.1182/blood-213-08-518886
• 8 Greenberg PL, Tuechler H, Schanz J. et al Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120 (12) 2454-2465 . doi:10.1182/blood-2012-03-420489
• 9 Neukirchen J, Lauseker M, Blum S. et al Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leuk Res 2014; 38 (01) 57-64 . doi:10.1016/j.leukres-2013.10.013
• 10 Zipperer E, Tanha N, Strupp C. et al The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica 2014; 99 (03) 31-32 . doi:10.3324/Haematol.2013.101055
• 11 Santini V, Schemenau J, Levis A. et al Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood 2013; 26: 2286-2288 . doi:10.1181/blood-2013-07-512442
• 12 Schuler E, Giagounidis A, Haase D. et al Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia 2016; 30: 1580-1582 . doi:10.1038/leu.2015.340
• 13 Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008; 88: 24-29 . doi:10.1007/s12185-017-2367-1
• 14 Platzbecker U, Germing U, Götze K. et al Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017; 18: 1338-1347 . doi:10.1016/S1470-2045(17)30615-0
• 15 Geyh S, Oz S, Cadeddu RP. et al Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27 (09) 1841-1851 . doi:10.1038/leu.2013.193
• 16 Götze K, Platzbecker U, Giagounidis A. et al Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 2010; 89: 841-850 . doi:10.1007/s00277-010-1015-0
• 17 Kobbe G, Schroeder T, Rautenberg C. et al Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes. Expert Rev Hematol 2019; 12: 821-831 . doi:10.1080/17474086.2019.1645004
• 18 Kasprzak A, Nachtkamp K, Kondakci M. et al Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes. Ann Hematol, under review
• 19 Rautenberg C, Germing U, Pechtel S. et al Prognostic impact of peripheral blood WT1-RNS expression in patients with MDS. Blood cancer journal 2019; 12: 86 . doi:10.1038/s41408-019-1248-y
• 20 Bernard E, Nannya Y, Hasserjian RP. et al Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 2020; [in press] DOI: 10.1038/s41591-020-1008-z.